Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein arginine methyltransferase 1 (PRMT1) is the predominant type I protein arginine methyltransferase in mammals. It catalyzes the transfer of methyl groups from S-adenosyl-L-methionine (SAM) to the guanidino nitrogens of arginine residues in target proteins, resulting in monomethylation and asymmetric dimethylation. This post-translational modification plays a crucial role in regulating gene expression, chromatin remodeling, signal transduction, RNA processing, and other cellular processes. Dysregulation of PRMT1 has been implicated in various human diseases including cancer, making it a therapeutic target.
Inhibition of protein arginine methylation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Arginine Methyltransferase 1 (PRMT1).